Clinical Drug Investigation

, Volume 36, Issue 5, pp 331–340 | Cite as

Plant-Derived and Endogenous Cannabinoids in Epilepsy

  • Alberto VerrottiEmail author
  • Miriam Castagnino
  • Mauro Maccarrone
  • Filomena FezzaEmail author
Current Opinion


Cannabis is one of the oldest psychotropic drugs and its anticonvulsant properties have been known since the last century. The aim of this reveiw was to analyze the efficacy of cannabis in the treatment of epilepsy in adults and children. In addition, a description of the involvement of the endocannabinoid system in epilepsy is given in order to provide a biochemical background to the effects of endogenous cannabinoids in our body. General tolerability and adverse events associated with cannabis treatment are also investigated. Several anecdotal reports and clinical trials suggest that in the human population cannabis has anticonvulsant properties and could be effective in treating partial epilepsies and generalized tonic-clonic seizures, still known as “grand mal.” They are based, among other factors, on the observation that in individuals who smoke marijuana to treat epilepsy, cessation of cannabis use precipitates the re-emergence of convulsive seizures, whereas resuming consumption of this psychotropic drug controls epilepsy in a reproducible manner. In conclusion, there is some anecdotal evidence for the potential efficacy of cannabis in treating epilepsy. Though there has been an increased effort by patients with epilepsy, their caregivers, growers, and legislators to legalize various forms of cannabis, there is still concern about its efficacy, relative potency, availability of medication-grade preparations, dosing, and potential short- and long-term side effects, including those on prenatal and childhood development.


Fatty Acid Amide Hydrolase Anticonvulsant Property Medical Marijuana Dravet Syndrome Expanded Access Program 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Compliance with Ethical Standards

Financial disclosure

The authors have no financial relationships to disclose with regard to this article.

Conflict of interest

AV, MC, MM and FF have no conflicts of interest.


  1. 1.
    Ben Amar M, L´eonard L. Chapter 16: Cannabis. In: L´eonard L, Ben Amar M, editors. Les Psychotropes: Pharmacologie et Toxicomanie. Montreal: Les Presses de l’Universit´e de Montr´eal; 2002. p. 571–627.Google Scholar
  2. 2.
    O’Shaugnessy WB. On the preparations of the Indian hemp, or gunjah (Cannabis indica): their effects on the animal system in health, and their utility in the treatment of tetanus and other convulsive diseases. Transactions of Medical and Physical Society of Bengal, 1838–1840. p. 421–461.Google Scholar
  3. 3.
    Robson P. Therapeutic aspects of cannabis and CBss. BrJ Psychiatry. 2001;178:107–15.CrossRefGoogle Scholar
  4. 4.
    Carter GT, Weijdt P, Kyashna-Tocha M, Abrams DI. Medicinal cannabis: rational guidelines for dosing. Drugs. 2004;75:464–70.Google Scholar
  5. 5.
    Fankhauser M. Chapter 4: history of cannabis in Western medicine. In: Grotenhermen F, Russo R, editors. Cannabis and CBss: pharmacology, toxicology and therapeutic potential. New York: The Haworth Integrative Healing Press; 2002. p. 37–51.Google Scholar
  6. 6.
    Ben Amar M. Cannabinoids in medicine: a review of their therapeutic potential. J Ethnopharmacol. 2006;105:1–25.Google Scholar
  7. 7.
    Mirken B. Marijuana on the state. Lancet. 2004;364:842.CrossRefPubMedGoogle Scholar
  8. 8.
    Hoey J. Marijuana: federal smoke clears a little. CMAJ. 2001;164:1397.Google Scholar
  9. 9.
    Health Canada. Medical Use of Marihuana. Stakeholder Statistics. Ottawa: Office of Cannabis Medical Access, Health Canada; 2005. p. 2.Google Scholar
  10. 10.
    Gorter RW, Butorac M, Pulido Cobian E, van der Sluis W. Medical use of cannabis in the Netherlands. Neurology. 2005;64:917–9.CrossRefPubMedGoogle Scholar
  11. 11.
    Health Canada CIHR. Medical Marihuana Research Program. Ottawa: Health Canada and Canadian Institutes of Health Research; 1999. p. 7.Google Scholar
  12. 12.
    Health Canada [website]. Medical use of marijuana. Ottawa: Health Canada; 2015. Available from: Accessed 10 July 2015.
  13. 13.
    Collège des médecins du Québec. Guidelines concerning the prescription of dried cannabis for medical purposes. Montreal: Collège des médecins du Québec; 2014. Available from: Accessed 10 July 2015.
  14. 14.
    Izzo AA, Borrelli F, Capasso R, Di Marzo V, Mechoulam R. Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb. Trends Pharmacol Sci. 2009;30:515–27.CrossRefPubMedGoogle Scholar
  15. 15.
    McKim WA. Drugs and behavior. An introduction to behavioral pharmacology, 4th ed. Upper Saddle River: Prentice-Hall; 2000. p. 400.Google Scholar
  16. 16.
    Pertwee RG, Howlett AC, Abood ME, Alexander SP, Di Marzo V, Elphick MR, Greasley PJ, Hansen HS, Kunos G, Mackie K, Mechoulam R, Ross RA. International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB1 and CB2. Pharmacol Rev. 2010;62:588–631.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Fezza F, Bari M, Florio R, Talamonti E, Feole M, Maccarrone M. Endocannabinoids, related compounds and their metabolic routes. Molecules. 2014;19:17078–106.CrossRefPubMedGoogle Scholar
  18. 18.
    Viscomi MT, Oddi S, Latini L, Pasquariello N, Florenzano F, Bernardi G, Molinari M, Maccarrone M. Selective CB2 receptor agonism protects central neurons from remote axotomy-induced apoptosis through the PI3K/Akt pathway. J Neurosci. 2009;29:4564–70.CrossRefPubMedGoogle Scholar
  19. 19.
    Ross RA. Allosterism and cannabinoid CB(1) receptors: the shape of things to come. Trends Pharmacol Sci. 2007;28:567–72.CrossRefPubMedGoogle Scholar
  20. 20.
    Galve-Roperh I, Rueda D, Gómez del Pulgar T, Velasco G, Guzmán M. Mechanism of extracellular signal-regulated kinase activation by the CB(1) cannabinoid receptor. Mol Pharmacol. 2002;62:1385–92.CrossRefPubMedGoogle Scholar
  21. 21.
    Sánchez C, de Ceballos ML, Gomez del Pulgar T, Rueda D, Corbacho C, Velasco G, Galve-Roperh I, Huffman JW, Ramón y Cajal S, Guzmán M. Inhibition of glioma growth in vivo by selective activation of the CB(2) cannabinoid receptor. Cancer Res. 2001;61:5784–89.Google Scholar
  22. 22.
    Schmid HHO, Schmid PC, Natarajan V. N-Acylated glycerophospholipids and their derivatives. Prog Lipid Res. 1990;29:1–43.CrossRefPubMedGoogle Scholar
  23. 23.
    Jin XH, Uyama T, Wang J, Okamoto Y, Tonai T, Ueda N. cDNA cloning and characterization of human and mouse Ca(2+)-independent phosphatidylethanolamine N-acyltransferases. Biochim Biophys Acta. 2009;1791:32–8.CrossRefPubMedGoogle Scholar
  24. 24.
    Okamoto Y, Morishita J, Tsuboi K, Tonai T, Ueda N. Molecular characterization of a phospholipase D generating anandamide and its congeners. J Biol Chem. 2004;279:5298–305.CrossRefPubMedGoogle Scholar
  25. 25.
    Simon GM, Cravatt BF. Endocannabinoid biosynthesis proceeding through glycerophospho-N-acyl ethanolamine and a role for alpha/beta-hydrolase 4 in this pathway. J Biol Chem. 2006;281:26465–72.CrossRefPubMedGoogle Scholar
  26. 26.
    Liu J, Wang L, Harvey-White J, Osei-Hyiaman D, Razdan R, Gong Q, Chan AC, Zhou Z, Huang BX, Kim HY, Kunos G. A biosynthetic pathway for anandamide. Proc Natl Acad Sci. 2006;103:13345–50.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Simon GM, Cravatt BF. Anandamide biosynthesis catalyzed by the phosphodiesterase GDE1 and detection of glycerophospho-N-acyl ethanolamine precursors in mouse brain. J Biol Chem. 2008;283:9341–9.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Cravatt BF, Giang DK, Mayfield SP, Boger DL, Lerner RA, Gilula NB. Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature. 1996;384:83–7.CrossRefPubMedGoogle Scholar
  29. 29.
    Wei BQ, Mikkelsen TS, McKinney MK, Lander ES, Cravatt BF. A second fatty acid amide hydrolase with variable distribution among placental mammals. J Biol Chem. 2006;281:36569–78.CrossRefPubMedGoogle Scholar
  30. 30.
    Tsuboi K, Sun YX, Okamoto Y, Araki N, Tonai T, Ueda N. Molecular characterization of N-acylethanolamine-hydrolyzing acid amidase, a novel member of the choloylglycine hydrolase family with structural and functional similarity to acid ceramidase. J Biol Chem. 2005;280:11082–92.CrossRefPubMedGoogle Scholar
  31. 31.
    Bisogno T, Howell F, Williams G, Minassi A, Cascio MG, Ligresti A, Matias I, Schiano-Moriello A, Paul P, Williams EJ, Gangadharan U, Hobbs C, Di Marzo V, Doherty P. Cloning of the first sn1-DAG lipases points to the spatial and temporal regulation of endocannabinoid signaling in the brain. J Cell Biol. 2003;163:463–8.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Dinh TP, Carpenter D, Leslie FM, Freund TF, Katona I, Sensi SL, Kathuria S, Piomelli D. Brain monoglyceride lipase participating in endocannabinoid inactivation. Proc Natl Acad Sci. 2002;99:10819–24.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Navia-Paldanius D, Savinainen JR, Laitinen JT. Biochemical and pharmacological characterization of human α/β-hydrolase domain containing 6 (ABHD6) and 12 (ABHD12). J Lipid Res. 2012;53:2413–24.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Ueda N, Tsuboi K, Uyama T. Metabolism of endocannabinoids and related N-acylethanolamines: canonical and alternative pathways. FEBS J. 2013;280:1874–94.CrossRefPubMedGoogle Scholar
  35. 35.
    Ueda N, Tsuboi K, Uyama T. N-Acylethanolamine metabolism with special reference to N-acylethanolamine-hydrolyzing acid amidase (NAAA). Prog Lipid Res. 2010;49:299–315.CrossRefPubMedGoogle Scholar
  36. 36.
    Rouzer CA, Marnett LJ. Endocannabinoid oxygenation by cyclooxygenases, lipoxygenases, and cytochromes P450: cross-talk between the eicosanoid and endocannabinoid signaling pathways. Chem Rev. 2011;111:5899–921.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Romigi A, Bari M, Placidi F, Marciani MG, Malaponti M, Torelli F, Izzi F, Prosperetti C, Zannino S, Corte F, Chiaramonte C, Maccarrone M. Cerebrospinal fluid levels of the endocannabinoid anandamide are reduced in patients with untreated newly diagnosed temporal lobe epilepsy. Epilepsia. 2010;51:768–72.CrossRefPubMedGoogle Scholar
  38. 38.
    Soltesz I, Alger BE, Kano M, Lee SH, Lovinger DM, Ohno-Shosaku T, Watanabe M. Weeding out bad waves: towards selective cannabinoid circuit control in epilepsy. Nat Rev Neurosci. 2015;16:264–77.CrossRefPubMedGoogle Scholar
  39. 39.
    Wallace MJ, Blair RE, Falenski KW, Martin BR, De Lorenzo RJ. The endogenous cannabinoid system regulates seizure frequency and duration in a model of temporal lobe epilepsy. J Pharmacol Exp Ther. 2003;307:129–37.CrossRefPubMedGoogle Scholar
  40. 40.
    Fezza F, Marrone MC, Avvisati R, Di Tommaso M, Lanuti M, Rapino C, Mercuri NB, Maccarrone M, Marinelli S. Distinct modulation of the endocannabinoid system upon kainic acid-induced in vivo seizures and in vitro epileptiform bursting. Mol Cell Neurosci. 2014;62:1–9.CrossRefPubMedGoogle Scholar
  41. 41.
    Citraro R, Russo E, Ngomba RT, Nicoletti F, Scicchitano F, Whalley BJ, Calignano A, De Sarro G. CB1 agonists, locally applied to the cortico-thalamic circuit of rats with genetic absence epilepsy, reduce epileptic manifestations. Epilepsy Res. 2013;106:74–82.CrossRefPubMedGoogle Scholar
  42. 42.
    Rizzo V, Ferraro G, Carletti F, Lonobile G, Cannizzaro C, Sardo P. Evidences of cannabinoids-induced modulation of paroxysmal events in an experimental model of partial epilepsy in the rat. Neurosci Lett. 2009;462:135–9.CrossRefPubMedGoogle Scholar
  43. 43.
    Clement AB, Hawkins EG, Lichtman AH, Cravatt BF. Increased seizure susceptibility and proconvulsant activity of anandamide in mice lacking fatty acid amide hydrolase. J Neurosci. 2003;23:3916–23.PubMedGoogle Scholar
  44. 44.
    Deshpande LS, Blair RE, Ziobro JM, Sombati S, Martin BR, DeLorenzo RJ. Endocannabinoids block status epilepticus in cultured hippocampal neurons. Eur J Pharmacol. 2007;558:52–9.CrossRefPubMedPubMedCentralGoogle Scholar
  45. 45.
    Carletti F, Gambino G, Rizzo V, Ferraro G, Sardo P. Cannabinoid and nitric oxide signaling interplay in the modulation of hippocampal hyperexcitability: study on electrophysiological and behavioral models of temporal lobe epilepsy in the rat. Neuroscience. 2015;303:149–59.CrossRefPubMedGoogle Scholar
  46. 46.
    Shubina L, Aliev R, Kitchigina V. Attenuation of kainic acid-induced status epilepticus by inhibition of endocannabinoid transport and degradation in guinea pigs. Epilepsy Res. 2015;111:33–44.CrossRefPubMedGoogle Scholar
  47. 47.
    Karanian DA, Karim SL, Wood JT, Williams JS, Lin S, Makriyannis A, Bahr BA. Endocannabinoid enhancement protects against kainic acid-induced seizures and associated brain damage. J Pharmacol Exp Ther. 2007;322:1059–66.Google Scholar
  48. 48.
    Marsicano G, Goodenough S, Monory K, Hermann H, Eder M, Cannich A, Azad SC, Cascio MG, Gutiérrez SO, van der Stelt M, López-Rodriguez ML, Casanova E, Schütz G, Zieglgänsberger W, Di Marzo V, Behl C. Lutz B CB1 cannabinoid receptors and on-demand defense against excitotoxicity. Science. 2003;302:84–8.CrossRefPubMedGoogle Scholar
  49. 49.
    Naidoo V, Karanian DA, Vadivel SK, Locklear JR, Wood JT, Nasr M, Quizon PM, Graves EE, Shukla V, Makriyannis A, Bahr BA. Equipotent inhibition of fatty acid amide hydrolase and monoacylglycerol lipase—dual targets of the endocannabinoid system to protect against seizure pathology. Neurotherapeutics. 2012;9:801–13.CrossRefPubMedPubMedCentralGoogle Scholar
  50. 50.
    Mechoulam R. Chapter 1: the pharmacohistory of Cannabis sativa. In: Mechoulan R, editor. CBss as therapeutic agents. Boca Raton: CRC Press; 1986. p. 1–19.Google Scholar
  51. 51.
    Consroe P, Wood JC, Buchsbaum H. Anticonvulsant nature of marihuana smoking. JAMA. 1975;234:306–7.CrossRefPubMedGoogle Scholar
  52. 52.
    Ellison JM, Gelwan E, Ogletree J. Complex partial seizure symptoms affected by marijuana abuse. J Clin Psychiatry. 1990;51:439–40.PubMedGoogle Scholar
  53. 53.
    Grinspoon L, Bakalar JB. Marihuana. The Forbidden Medicine. New Haven: Yale University Press; 1997. p. 296.Google Scholar
  54. 54.
    Gurley RJ, Aranow R, Katz M. Medicinal marijuana: a comprehensive review. J Psychoactive Drugs. 1998;30:137–47.CrossRefPubMedGoogle Scholar
  55. 55.
    Carlini EA, Mechoulam R, Lander N. Anticonvulsant activity of four oxygenated cannabidiol derivatives. Res Commun Chem Pathol Pharmacol. 1975;12:1–15.PubMedGoogle Scholar
  56. 56.
    Ames FR, Cridland S. Anticonvulsant effect of cannabidiol. S Afr Med J. 1985;69:14.Google Scholar
  57. 57.
    Cortesi M, Fusar-Poli P. Potential therapeutical effects of cannabidiol in children with pharmacoresistant epilepsy. Med Hypotheses. 2007;68:920–1.CrossRefPubMedGoogle Scholar
  58. 58.
    Luszczki JJ, Czuczwar P, Cioczek-Czuczwar A, Czuczwar SJ. Arachidonyl- 2′-chloroethylamide, a highly selective CBs CB1 receptor agonist, enhances the anticonvulsant action of valproate in the mouse maximal electroshock- induced seizure model. Eur J Pharmacol. 2006;547:65–74.CrossRefPubMedGoogle Scholar
  59. 59.
    Monory K, Massa F, Egertová M, Eder M, Blaudzun H, Westenbroek R, Kelsch W, Jacob W, Marsch R, Ekker M, Long J, Rubenstein JL, Goebbels S, Nave KA, During M, Klugmann M, Wölfel B, Dodt HU, Zieglgänsberger W, Wotjak CT, Mackie K, Elphick MR, Marsicano G, Lutz B. The endocannabinoid system controls key epileptogenic circuits in the hippocampus. Neuron. 2006;51:455–66.CrossRefPubMedPubMedCentralGoogle Scholar
  60. 60.
    Gordon E, Devinsky O. Alcohol and marijuana: effects on epilepsy and use by patients with epilepsy. Epilepsia. 2001;42:1266–72.CrossRefPubMedGoogle Scholar
  61. 61.
    Keeler MH, Reifler CB. Grand mal convulsions subsequent to marijuana use. Case report. Dis Nerv Syst. 1967;28:474–5.PubMedGoogle Scholar
  62. 62.
    Cunha JM, Carlini EA, Pereira AE, et al. Chronic administration of cannabidiol to healthy volunteers 2 and epileptic patients. Pharmacology. 1980;21:175–85.CrossRefPubMedGoogle Scholar
  63. 63.
    Gloss D, Vickrey B. Cannabinoids for epilepsy. Cochrane Database Syst Rev. 2014;3:CD009270.Google Scholar
  64. 64.
    Davis JP, Ramsey HH. Anti-epileptic action of marijuana active substances. Fed Proc. 1949;8:167.Google Scholar
  65. 65.
    Feeney DM. Marihuana use among epileptics. JAMA. 1976;235:1105.CrossRefPubMedGoogle Scholar
  66. 66.
    Mechoulam R, Carlini EA. Toward drugs derived from cannabis. Naturwissenschaften. 1978;65:174–9.CrossRefPubMedGoogle Scholar
  67. 67.
    Koppel BS, Brust JC, Fife T, Bronstein J, Youssof S, Gronseth G, Gloss D. Systematic review: efficacy and safety of medical marijuana in selected neurologic disorders: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2014;82:1556–63.CrossRefPubMedPubMedCentralGoogle Scholar
  68. 68.
    Trembly B, Sherman M. Double-blind clinical study of cannabidiol as a secondary anticonvulsant. In: Marijuana ’90 International Conference on Cannabis and Cannabinoids; 1990 July 8–11, section 2. Kolympari: International Association for CBs Medicines; 1990. p. 5.Google Scholar
  69. 69.
    Dos Santos RG, Hallak JE, Leite JP, Zuardi AW, Crippa JA. Phytocannabinoids and epilepsy. J Clin Pharm Ther. 2015;40:135–43.CrossRefPubMedGoogle Scholar
  70. 70.
    Geffrey AL, Pollack SF, Bruno PL, Thiele EA. Drug-drug interaction between clobazam and cannabidiol in children with refractory epilepsy. Epilepsia. 2015;56:1246–51.CrossRefPubMedGoogle Scholar
  71. 71.
    Yamaori S, Ebisawa J, Okushima Y, et al. Potent inhibition of human cytochrome P450 3A isoforms by cannabidiol: role of phenolic hydroxyl groups in the resorcinol moiety. Life Sci. 2011;88:730–6.CrossRefPubMedGoogle Scholar
  72. 72.
    Jiang R, Yamaori S, Okamoto Y, et al. Cannabidiol is a potent inhibitor of the catalytic activity of cytochrome P450 2C19. Drug Metab Pharmacokinet. 2013;28:332–8.CrossRefPubMedGoogle Scholar
  73. 73.
    Macleod J, Oakes R, Copello A, Crome I, Egger M, Hickman M, Oppenkowski T, Stokes-Lampard H, Davey Smith G. Psychological and social sequelae of cannabis and other illicit drug use by young people: a systematic review of longitudinal, general population studies. Lancet. 2004;363:1579–88.CrossRefPubMedGoogle Scholar
  74. 74.
    Arseneault L, Cannon M, Poulton R, Murray R, Caspi A, Moffitt TE. Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study. BMJ. 2002;325:1212–3.CrossRefPubMedPubMedCentralGoogle Scholar
  75. 75.
    Porter BE, Jacobson C. Report of a parent survey of cannabidiol-enriched cannabis use in pediatric treatment-resistant epilepsy. Epilepsy Behav. 2013;29:574–7.CrossRefPubMedPubMedCentralGoogle Scholar
  76. 76.
    Friedman D, Devinsky O. Cannabinoids in the treatment of epilepsy. N Engl J Med. 2015;10(373):1048–58.Google Scholar
  77. 77.
    Devinsky O, et al. Epidiolex (Cannabidiol) in treatment resistant epilepsy, American Epilepsy Society Annual Meeting, Poster, December 7, 2015.Google Scholar
  78. 78.
    Lorentzos MS, Webster R. Cannabinoids for paediatric epilepsy: weeding out the issues. J Paediatr Child Health. 2015;51:476–7.CrossRefGoogle Scholar
  79. 79.
    Szaflarski JP, Bebin EM. Cannabis, cannabidiol, and epilepsy–from receptors to clinical response. Epilepsy Behav. 2014;41:277–82.CrossRefPubMedGoogle Scholar
  80. 80.
    Ng SKC, Brust JCM, Hauser WA, Susser M. Illicit drug use and the risk of new-onset seizures. Am J Epidemiol. 1990;132:47–57.PubMedGoogle Scholar
  81. 81.
    Lorenz R. Experiences with THC-treatment in children and adolescents. In: IACM 2nd Conference on CBss in Medicine. Koeln: International Association for Cannabis as Medicine; 2003. p. 6.Google Scholar
  82. 82.
    Gross DW, Hamm J, Ashowrth NL, Quigley D. Marijuana use and epilepsy. Neurology. 2004;62:2095–7.CrossRefPubMedGoogle Scholar
  83. 83.
    Mortati K, Dworetzky B, Devinsky O. Marijuana: an effective treatment in partial epilepsy? A case report and review of the literature. Rev Neurol Dis. 2007;4:103–6.PubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2016

Authors and Affiliations

  1. 1.Department of PediatricsUniversity of L’Aquila, Ospedale “San Salvatore”L’AquilaItaly
  2. 2.Department of PediatricsUniversity of Perugia, Ospedale “Santa Maria della Misericordia”PerugiaItaly
  3. 3.Department of MedicineCampus Bio-Medico University of RomeRomeItaly
  4. 4.European Center for Brain Research/IRCCS Santa Lucia FoundationRomeItaly
  5. 5.Department of Experimental Medicine and SurgeryTor Vergata University of RomeRomeItaly

Personalised recommendations